{
    "clinical_study": {
        "@rank": "116165", 
        "arm_group": [
            {
                "arm_group_label": "Hialuronic acid", 
                "arm_group_type": "Active Comparator", 
                "description": "Single intraarticular injection of Hyaluronic acid (Hyal One)"
            }, 
            {
                "arm_group_label": "Hyaluronic acid and MSC 10", 
                "arm_group_type": "Active Comparator", 
                "description": "Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells"
            }, 
            {
                "arm_group_label": "Hyaluronic acid AND MSC 100", 
                "arm_group_type": "Active Comparator", 
                "description": "Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells"
            }
        ], 
        "brief_summary": {
            "textblock": "Purpose:  To determine the safety, feasibility and effectiveness (clinical and radiological)\n      of intra-articular administration of autologous mesenchymal stem cells (MSCs) in patients\n      with knee osteoarthritis.\n\n      Patients and methods\n\n      Clinical trial phase I- II, randomized , multicenter , with three treatment arms and 10\n      patients for each group. The investigators compare the intraarticular injection of\n      hialuronic acid against the administration of two different doses of mesenchymal stem cells\n      with hialuronic acid according to the following scheme:\n\n        1. Group A: intra-articular injection of hyaluronic acid (Hyalone\u00ae). Single dose.\n\n        2. Group B: Low Dosage of MSCs . Intra-articular injection of 10 million autologous\n           mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile small\n           volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an\n           intraarticular injection Hiaur\u00f3nico Acid ( Hyalone\u00ae).\n\n        3. Group C : High dose of MSCs. Intra-articular injection of 100 million autologous\n           mesenchymal progenitor stem cells cultured ex - vivo ( cell suspension sterile small\n           volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an\n           intraarticular injection Hiaur\u00f3nico Acid (Hyalone\u00ae).\n\n      The primary endpoint is safety and feasibility. The investigators registered the occurrence\n      of complications and / or adverse effects during the study.\n\n      In addition the investigators assess the response to intra-articular infusion of CMM\n      analyzing the following parameters:\n\n        -  Clinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since\n           treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.\n\n        -  Radiographic (baseline, 6 and 12 months since treatment): Femorotibial space.\n\n        -  Radiographic using MRI (baseline, 6 and 12 months since treatment): by assessing the\n           number location of the lesions , cartilage thickness , signal intensity , subchondral\n           bone alteration , volume and WORMS and dGEMRIC protocols."
        }, 
        "brief_title": "Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarthritis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "detailed_description": {
            "textblock": "Purpose:  To determine the safety, feasibility and effectiveness (clinical and radiological)\n      of intra-articular administration of autologous mesenchymal stem cells (MSCs) in patients\n      with knee osteoarthritis.\n\n      Patients and methods\n\n      Clinical trial phase I- II, randomized , multicenter , with three treatment arms and 10\n      patients for each group. The investigators compare the intraarticular injection of\n      hialuronic acid against the administration of two different doses of mesenchymal stem cells\n      with hialuronic acid according to the following scheme:\n\n        1. Group A: intra-articular injection of hyaluronic acid (Hyalone\u00ae). Single dose.\n\n        2. Group B: Low Dosage of MSCs . Intra-articular injection of 10 million autologous\n           mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile small\n           volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an\n           intraarticular injection Hiaur\u00f3nico Acid ( Hyalone\u00ae).\n\n        3. Group C : High dose of MSCs. Intra-articular injection of 100 million autologous\n           mesenchymal progenitor stem cells cultured ex - vivo ( cell suspension sterile small\n           volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an\n           intraarticular injection Hiaur\u00f3nico Acid (Hyalone\u00ae).\n\n      The autologous mesenchymal stem cells are obtained from the iliac crest and cultured ex vivo\n      under local anesthesia and sedation.\n\n      The primary endpoint is safety and feasibility. The investigators registered the occurrence\n      of complications and / or adverse effects during the study.\n\n      In addition the investigators assess the response to intra-articular infusion of CMM\n      analyzing the following parameters:\n\n        -  Clinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since\n           treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.\n\n        -  Radiographic (baseline, 6 and 12 months since treatment): Femorotibial space.\n\n        -  Radiographic using MRI (baseline, 6 and 12 months since treatment): by assessing the\n           number location of the lesions , cartilage thickness , signal intensity , subchondral\n           bone alteration , volume and WORMS and dGEMRIC protocols.\n\n      All patients met the following inclusion and exclusion criteria:\n\n      Inclusion Criteria:\n\n        -  Males and females between 50 and 80 year old.\n\n        -  Diagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American\n           College of Rheumatology).\n\n        -  Joint pain equal or greater than 2.5 points on the visual analogue scale (VAS).\n\n        -  Radiological Classification: Kellgren-Lawrence scale greater or equal to 2.\n\n        -  Body mass index between 20 and 35 kg/m2.\n\n        -  Ability to follow during the study period.\n\n      Exclusion Criteria:\n\n        -  Bilateral Osteoarthritis of the Knee requiring treatment in both knees.\n\n        -  Previous diagnosis of polyarticular disease.\n\n        -  Severe mechanical deformation.\n\n        -  Arthroscopy during the previous 6 months.\n\n        -  Intraarticular infiltration of hyaluronic acid in the last 6 months.\n\n        -  Systemic autoimmune rheumatic disease.\n\n        -  Poorly controlled diabetes mellitus.\n\n        -  Blood dyscrasias.\n\n        -  Immunosuppressive or anticoagulant treatments.\n\n        -  Treatment with corticosteroids in the 3 months prior to inclusion in the study.\n\n        -  NSAID therapy within 15 days prior to inclusion in the study.\n\n        -  Patients with a history of allergy to penicillin or streptomycin.\n\n        -  Allergy to hyaluronic acid or poultry proteins."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females between 50 and 80 year old.\n\n          -  Diagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American\n             College of Rheumatology).\n\n          -  Joint pain equal or greater than 2.5 points on the visual analogue scale (VAS).\n\n          -  Radiological Classification: Kellgren-Lawrence scale greater or equal to 2.\n\n          -  Body mass index between 20 and 35 kg/m2.\n\n          -  Ability to follow during the study period.\n\n        Exclusion Criteria:\n\n          -  Bilateral Osteoarthritis of the Knee requiring treatment in both knees.\n\n          -  Previous diagnosis of polyarticular disease.\n\n          -  Severe mechanical deformation.\n\n          -  Arthroscopy during the previous 6 months.\n\n          -  Intraarticular infiltration of hyaluronic acid in the last 6 months.\n\n          -  Systemic autoimmune rheumatic disease.\n\n          -  Poorly controlled diabetes mellitus.\n\n          -  Blood dyscrasias.\n\n          -  Immunosuppressive or anticoagulant treatments.\n\n          -  Treatment with corticosteroids in the 3 months prior to inclusion in the study.\n\n          -  NSAID therapy within 15 days prior to inclusion in the study.\n\n          -  Patients with a history of allergy to penicillin or streptomycin.\n\n          -  Allergy to hyaluronic acid or poultry proteins."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02123368", 
            "org_study_id": "CMM/ART", 
            "secondary_id": "2009-017624-72"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Hialuronic acid", 
                    "Hyaluronic acid and MSC 10", 
                    "Hyaluronic acid AND MSC 100"
                ], 
                "description": "Single intraarticular injection of Hyaluronic acid (Hyal One)", 
                "intervention_name": "Hyaluronic acid", 
                "intervention_type": "Drug", 
                "other_name": "HyalOne"
            }, 
            {
                "arm_group_label": "Hyaluronic acid and MSC 10", 
                "description": "10 million of Bone marrow mesenchimal stem cells", 
                "intervention_name": "10 million Bone marrow mesenchimal stem cells", 
                "intervention_type": "Biological", 
                "other_name": "10 million Bone marrow mesenchimal stem cells"
            }, 
            {
                "arm_group_label": "Hyaluronic acid AND MSC 100", 
                "description": "100 million of Bone marrow mesenchimal stem cells", 
                "intervention_name": "100 million Bone marrow mesenchimal stem cells", 
                "intervention_type": "Biological", 
                "other_name": "100 million Bone marrow mesenchimal stem cells"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hyaluronic Acid"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Osteoarthritis", 
            "Mesenchimal stem cell", 
            "Knee"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "link": {
            "description": "University clinic of navarre trial information", 
            "url": "http://www.cun.es/actualidad/noticias/celulas-madre-osea-artrosis-rodilla"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Salamanca", 
                        "country": "Spain", 
                        "state": "Castilla y Le\u00f3n", 
                        "zip": "37007"
                    }, 
                    "name": "Traumatology department. Complejo Hospitalario de Salamanca"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pamplona", 
                        "country": "Spain", 
                        "state": "Navarra", 
                        "zip": "31008"
                    }, 
                    "name": "Orthopaedic and traumatology department. Cl\u00ednica Universidad de Navarra"
                }
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "3", 
        "official_title": "Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells", 
        "overall_official": [
            {
                "affiliation": "Clinica Universidad de Navarra", 
                "last_name": "Jos\u00e9 Lamo-Espinosa, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Clinica Universidad de Navarra", 
                "last_name": "Felipe Prosper, MD PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Baseline Visual analogue scale (VAS)", 
                "measure": "Baseline Visual analogue scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "prior to the initial dose on day 1"
            }, 
            {
                "description": "Prior to the intervention on day 1  value of  knee injury and osteoarthritis outcome score (Koos).", 
                "measure": "Baseline value of  knee injury and osteoarthritis outcome score (Koos).", 
                "safety_issue": "No", 
                "time_frame": "Prior to the intervention on day 1"
            }, 
            {
                "description": "Prior to the intervention on day 1  Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).", 
                "measure": "Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).", 
                "safety_issue": "No", 
                "time_frame": "Prior to the intervention on day 1"
            }, 
            {
                "description": "Prior to the intervention on day 1 SF-36 value", 
                "measure": "Baseline SF-36 value", 
                "safety_issue": "No", 
                "time_frame": "Prior to the intervention on day 1"
            }, 
            {
                "description": "Pretreatment euroquol 5D value", 
                "measure": "Baseline euroquol 5D value", 
                "safety_issue": "No", 
                "time_frame": "Prior to the intervention on day 1"
            }, 
            {
                "description": "Prior to the intervention on day 1 Lequesne index", 
                "measure": "Baseline Lequesne index", 
                "safety_issue": "No", 
                "time_frame": "Prior to the intervention on day 1"
            }, 
            {
                "description": "Prior to the intervention femoritibial distance on rosenberg x-ray view", 
                "measure": "Baseline femorotibial distance", 
                "safety_issue": "No", 
                "time_frame": "Prior to the intervention"
            }, 
            {
                "description": "During the follow up", 
                "measure": "Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Follow up"
            }, 
            {
                "description": "Visual analogue scale (VAS) at on month", 
                "measure": "Visual analogue scale (VAS) at on month", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Visual analogue scale (VAS) at 3 months", 
                "measure": "Visual analogue scale (VAS) at 3 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Visual analogue scale (VAS) at 6 months", 
                "measure": "Visual analogue scale (VAS) at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Visual analogue scale (VAS) at 12 months", 
                "measure": "Visual analogue scale (VAS) at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Value of  knee injury and osteoarthritis outcome score (Koos) at 1 month", 
                "measure": "Value of  knee injury and osteoarthritis outcome score (Koos) at 1 month", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Value of  knee injury and osteoarthritis outcome score (Koos) at 3 month", 
                "measure": "Value of  knee injury and osteoarthritis outcome score (Koos) at 3 month", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "description": "Value of  knee injury and osteoarthritis outcome score (Koos) at 6 month", 
                "measure": "Value of  knee injury and osteoarthritis outcome score (Koos) at 6 month", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Value of  knee injury and osteoarthritis outcome score (Koos) at 12 months", 
                "measure": "Value of  knee injury and osteoarthritis outcome score (Koos) at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month", 
                "measure": "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month", 
                "measure": "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 3 month", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month", 
                "measure": "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months", 
                "measure": "Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "SF-36 value", 
                "measure": "SF-36 value at 1 month", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "SF 36 value at 3 months", 
                "measure": "SF 36 value at 3 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "SF 36 value at 6 months", 
                "measure": "SF 36 value at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "SF 36 value at 12 months", 
                "measure": "SF 36 value at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Euroquol 5D value at 1 month", 
                "measure": "Euroquol 5D value at 1 month", 
                "safety_issue": "No", 
                "time_frame": "1 MOnth"
            }, 
            {
                "description": "Euroquol 5D value at 3 months", 
                "measure": "Euroquol 5D value at 3 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Euroquol 5D value at 6 months", 
                "measure": "Euroquol 5D value at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Euroquol 5D value at 12 months", 
                "measure": "Euroquol 5D value at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Lequesne index at 1 month", 
                "measure": "Lequesne index at 1 month", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Lequesne index at 3 months", 
                "measure": "Lequesne index at 3 months", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Lequesne index at 6 months", 
                "measure": "Lequesne index at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Lequesne index at 12 months", 
                "measure": "Lequesne index at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Femorotibial distance at 6 months", 
                "measure": "Femorotibial distance at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Femorotibial distance at 12 months", 
                "measure": "Femorotibial distance at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Prior to the intervention MRI WORMS protocol", 
                "measure": "Baseline MRI WORMS protocol", 
                "safety_issue": "No", 
                "time_frame": "Prior to the intervention"
            }, 
            {
                "description": "MRI WORMS protocol score at 6 months", 
                "measure": "MRI WORMS protocol score at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "MRI WORMS protocol score at 12 months", 
                "measure": "MRI WORMS protocol score at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02123368"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Clinica Universidad de Navarra, Universidad de Navarra", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Clinica Universidad de Navarra, Universidad de Navarra", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}